PD-1-CD28 TCR T-cell therapy

N/A

Report date: 2025/03/20 15:37:39

Base Information

Drug NamePD-1-CD28 TCR T-cell therapy
Drug Alias NamePD-1-CD28 enhanced receptor TCR T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)anti-NY-ESO-1 TCR T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)enhanced neoantigen-reactive T-cell therapy (The First Affiliated Hospital of Zhengzhou University/Beijing Chineo)
ClassificationBiologics > Protein drugs > Recombinant proteinCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionHuman leukocyte antigen modulatorsCancer/testis antigen 1 modulators
TargetsCancer/testis antigen 1Human leukocyte antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaPreclinical
Originator CompaniesThe First Affiliated Hospital Of Zhengzhou University
China Registration ClassN/A

Develop Information

Active CompaniesBeijing Chineo Medical Technology Co LtdThe First Affiliated Hospital Of Zhengzhou University
Inactive CompaniesN/A
Active IndicationsSolid tumours
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A